tbuckley/cabot-search huggingface dataset:
Phase I study of satraplatin and docetaxel in solid malignancies
Authors: T. B. Leal, G. Wilding, J. Eickhoff, D. McNeel, D. Alberti, G. Liu
Journal: Journal of Clinical Oncology (2008)

2570 Background: Satraplatin (S) is a novel, orally administered platinum compound with broad antitumor activity. Preclincal studies have shown synergy with docetaxel (TAX). Here we report the results of a phase I study of S with TAX with and without G-CSF support in patients with advanced solid tumors. Methods: Patients with metastatic solid malignancies were enrolled. All pts had an ECOG performance status of < 2, adequate hematologic, renal and liver function. Prior chemotherapy/XRT had to have been completed 4 weeks prior to enrollment. Other exclusion criteria included prior XRT to > 30% of the marrow, neuropathy grade > 1, and previous platinum or TAX chemotherapy within 3 months of enrollment. TAX was given as a 1-hour infusion on day 1 (starting dose 60 mg/m2) in combination with S (starting dose 50 mg/m2/day, rounded to nearest 10 mg) administered orally in the fasted state, days 1–5 of a 21-day cycle. Results: 23 patients with a median of 3 prior cytotoxic chemotherapy regimens were enrolled. At dose level 1, 2/7 patients developed grade 3/4 neutropenia lasting > 5 days, exceeding the MTD. At dose level-1 (TAX 60 mg/m2, S 40 mg/m2/d), 1/6 patients developed grade 3/4 ANC. The protocol was subsequently amended to re-escalate with G-CSF (300 mcg SQ days 6–15) support. With G-CSF support, no DLT was observed and further dose escalation to level 2 (TAX 70 mg/m2, S 50 mg/m2/d) resulted in only 1/6 patients developing significant neutropenia. The most commonly reported adverse event was neutropenia (22%), followed by anemia, diarrhea and fatigue. Conclusions: The S and TAX combination is feasible with neutropenia as the main toxicity. Of note, this was a heavily pretreated cancer population. The recommended phase II dose is TAX 60 mg/m2 IV day 1 with SA 40 mg/m2 PO days 1–5, without G-CSF, and TAX 70 mg/m2 IV day 1 with SA 50 mg/m2 PO days 1–5, with G-CSF support, repeated in 3-week cycles. Preliminary data shows encouraging activity in men with high-grade castrate-refractory prostate cancer. As a result, this combination is currently being explored in an expanded cohort assessing the safety/tolerability/efficacy in men with chemo-naive, castrate-refractory prostate cancer. No significant financial relationships to disclose.
The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder
Authors: A. Dash, T. Koppie, K. Vora, B. Bochner, M. D. Galsky
Journal: Journal of Clinical Oncology (2005)

4586 Background: Neoadjuvant cisplatin-based combination chemotherapy improves survival in pts with (muscle-invasive) TCC of the bladder. While the data supporting adjuvant chemotherapy are somewhat less compelling, most consider post-operative chemotherapy an acceptable alternative. Many pts who may benefit from such therapy are not candidates for cisplatin due to impaired renal function. We sought to identify the proportion of pts ineligible for adjuvant chemotherapy based on renal impairment alone. Methods: We retrospectively reviewed all pts who underwent radical cystectomy for TCC at our institution between 1990 and 2004. Pts were excluded if they received neoadjuvant chemotherapy. Pts meeting our definition of ‘eligible’ for adjuvant therapy had ≥ pT3 and/or node positive disease. The nadir creatinine value obtained from weeks 6–12 post-cystectomy was used to calculate creatinine clearance (CrCl) using the Jellife formula. A CrCl of < 60 mL/min was considered inadequate for cisplatin-based chemotherapy. Results: 512 pts met the inclusion criteria for our analysis. Baseline characteristics included median age = 69.1 years (31.1–94.6), median serum creatinine = 0.9 mg/dL (0.2–2.8), and median CrCl = 65.8 mL/min (18–280). Sixty-one percent (312/512) had ≥ pT3N0/Nx disease and 39% had pTanyN+ disease. Based on a CrCl of < 60, 39.8% (204/512) of pts would be ineligible for adjuvant chemotherapy. The impact of age on eligibility is presented in the Table. Conclusions: Using calculated CrCl and a commonly used cut-off of 60 mL/min for cisplatin-based chemotherapy, up to 40% of patients with TCC who may benefit from adjuvant chemotherapy may be excluded on the basis of renal function alone. Clinical trials addressing this patient population are needed. No significant financial relationships to disclose.
Abstract 13442: Aging, Risk Factors and Progression of Coronary Atherosclerosis
Authors: Ayman A Hussein, Murat Tuzcu, Amy Hsu, Kiyoko Uno, Ozgur Bayturan, Samir kapadia, Paul Schoenhagen, Kathy Wolski, Steven Nissen, Stephen Nicholls
Journal: Circulation (2010)

Background: Increasing age is associated with greater morbidity and mortality from cardiovascular disease. The relationship between aging, burden and progression of coronary atherosclerosis (CAD) a...
Cervical Spondylosis and Its Neurological Complications.
Authors: Bernard H. Smith
Journal: Annals of Internal Medicine (1969)

ture, instructing patients before spirometry, and the placement of esophageal balloons. The tables of normal values are comprehensive and bring out the generally neglected fact that there are differences in lung volumes between ethnic groups. The reference list at the back of the book is lengthy and includes papers as late as 1967. The choice of articles seems good, and by being organized into convenient subject groupings, provides a handy guide to the literature on lung function. Robert M. Senior, MD St. Louis
Review of Legal Education in the United States and Canada for the Year 1932.
Authors: Alfred Zantzinger Reed
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea
Authors: James L. Januzzi, W. Frank Peacock, Alan S. Maisel, Claudia U. Chae, Robert L. Jesse, Aaron L. Baggish, Michelle O’Donoghue, Rahul Sakhuja, Annabel A. Chen, Roland R.J. van Kimmenade, Kent B. Lewandrowski, Donald M. Lloyd-Jones, Alan H.B. Wu
Journal: Journal of the American College of Cardiology (2007)
Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease. A phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
Authors: M. Pless, R. Stupp, R. Kann, A. Zouhair, M. Mayer, S. Thierstein, R. Stahel, D. Betticher, S. Balmer Majno, H. B. Ris
Journal: Journal of Clinical Oncology (2007)

18021 Background and Methods: Outcome of patients (pts) with locally advanced NSCLC treated with radio- or chemoradiotherapy is poor. This two-stage phase II trial (planned sample size 46) aimed at evaluating feasibility and outcome of a tri-modality concept of neoadjuvant chemotherapy (CT), radiotherapy (RT) followed by definitive surgery in operable, stage IIIB NSCLC pts. Treatment consisted of 3 cycles of cisplatin (100 mg/m 2 ) and docetaxel (85 mg/m 2 ) followed by accelerated, concomitant boost RT (44 Gy/22 fx) and surgery. Primary endpoint is event-free survival at 1 year. Operable pts up to age 75 and a performance status of 0–1 with stage IIIB NSCLC (pleural effusion excluded) were eligible. Results: Forty-five eligible pts (46 accrued) with a median age was 60 years (range 28–70) were treated between September 2001 and May 2006. Tumor location was right-sided in 28 pts and left-sided in 17 pts. Histology was squamous cell 42%, large cell 11%, adeno-13% and undifferentiated carcinoma 33%. N3-disease was present in 29%, T4 stage in 78%. CT (45 pts) and RT (34 pts) were delivered as prescribed in &gt;80% of cycles. The median time from enrollment to surgery was 3.7 months (2.8 - 5.2). The objective response rate after CT was 53% (95% c.i. 38–68%), after additional RT 67% (51–80%). Surgery (pneumonectomy in 17) was performed in 31 pts (69%), with an R0 resection in 24 pts. Median duration of hospitalization was 12 days (8–134). Two pts died in the perioperative phase due to ARDS and a cerebro-vascular event, respectively. Mature results of the primary endpoint and overall survival will be available at the ASCO meeting. Conclusions: Combined multimodality treatment strategy is feasible in a subgroup of patients, with acceptable toxicity. About two thirds of patients responded to the induction therapy, and were able to undergo subsequent surgery. No significant financial relationships to disclose.
Bronchiogenic Carcinoma and Adenoma, with a Chapter on Mediastinal Tumors.
Authors: B. M. Fried
Journal: Annals of Internal Medicine (1950)

The author of this monograph is well qualified to write on the subject of bronchiogenic carcinoma. His observations are based on an extensive personal experience with pulmonary neoplasms, and he has assembled together in one volume the conclusions reached by many authorities who have written about bronchiogenic carcinoma. Dr. Fried devotes considerable space to a discussion of the increasing incidence of cancer of the lung and concludes that this increase is more apparent than real. The discussion of the histogenesis of bronchial cancer and its classification is orthodox. The existence of primary alveolar cell carcinoma is denied. A rather lengthy chapter is devoted to the various theories of cancerogenesis in general and the etiology of bronchiogenic carcinoma in particular. A special supplementary chapter deals with the relationship between pulmonary tuberculosis and cancer of the lung. Those chapters devoted to the clinical manifestations and to the metastasis of pulmonary carcinoma are
Systematic evaluation of 2D versus M-mode echocardiography in mice, compared to ex vivo and in vivo MRI
Authors: D. J Stuckey, J. L Tremoleda, S Mcsweeney, L Fiedler, M Harada, C. A Carr, D. J Tyler, Willy Gsell, K Clarke, M. D Schneider
Journal: Cardiovascular Research (2012)
Renal insufficiency in bone metastasis cancer patients: Prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study
Authors: N. Janus, C. Le Tourneau, V. Launay-Vacher, J. Gligorov, O. Rixe, X. Pourrat, P. Beuzeboc, J. Morere, G. Deray, S. Oudard
Journal: Journal of Clinical Oncology (2007)

9121 Background: The IRMA study reported the high prevalence of renal insufficiency (RI) in 4684 solid tumour patients, with a glomerular filtration rate (GFR) &lt;90 ml/min for 50–60%. Furthermore, 80.1% were receiving nephrotoxic anticancer drugs and 79.9% drugs necessitating dosage adjustment. We present the results for IRMA patients with bone metastasis (BM). Methods: Subgroup analysis of IRMA patients with BM. Data collected: sex, age, weight, serum creatinine (SCR), bone metastasis (BM) and anticancer drugs. The prevalence of SCR&gt;110 μmol/L was assessed. GFR was estimated with Cockcroft-Gault (CG) and abbreviated MDRD (aMDRD) formulae. Drugs necessitating dosage adjustment and those potentially nephrotoxic were identified. Chi-square test was used to compare the prevalence of RI between patients with BM and patients without, for all patients and for breast cancer (BC) ones. Results: 1,000 patients (BC 577) with BM were included: median age 60, mean 59.8, weight 66 kg, 659 women. The prevalence of SCR&gt;110 μmol/L was 8.3%. That of GFR&lt;90 ml/min was 57.9% with CG and 54.7% with aMDRD. 83.4% of treated patients received at least one drug needing dosage adjustment (or no data) and 69% received at least one nephrotoxic drug. The prevalence of RI was not statistically different between patients with or without BM. However, the prevalence of RI was significantly higher in BC patients with BM as compared to BC patients without BM (62.1 versus 56.7 %, p=0.04). Conclusions: RI is highly frequent in cancer patients with BM. Appropriate evaluation of renal function necessitates CG or aMDRD calculation. In those patients, and especially in breast cancer patients with BM, anticancer drugs should be cautiously selected regarding their potential renal toxicity and need for dosage adjustment. [Table: see text] No significant financial relationships to disclose.
SLOWING THE SPEEDY: STRONG EVIDENCE THAT SPEED LIMITS REDUCE DEATHS
Authors: R West
Journal: BMJ (1988)

This brief article provided evidence to show that speed limits can reduce death and serious injury from road accidents and made out a case against the relaxation of the legal speed limits now in force. The introduction of speed limits resulted in appreciable reductions in death and serious injury from road traffic accidents in many countries: in Britain, the introduction of the 30 mph limit in 1935, and the introduction of the 40 mph limit in out of town areas led to a 15% and a 30% reduction respectively. The 50 km/hr speed limit introduction in towns in 1959 in Switzerland led to a 21% fall, and a similar limit in Germany produced a 30% decrease. The economic balance necessary between speed (journey time saved), and the risk of death or injury (years of life lost or impaired) was discussed briefly and the importance of taking the innocent victim into account in this equation was emphasized. The speeding motorist was not always the person affected by his actions: statistics have shown that when seat belt use became mandatory for drivers, deaths and serious injuries to passengers in the back seats, and to pedestrians and cyclists actually increased. Relaxation of the enforcement of laws on speeding would condemn some people to death.
Seizure Recognition and Treatment
Authors: Richard Lechtenberg
Journal: Annals of Internal Medicine (1990)

Part 1 Fundamental principles and evaluation: seizures and epilepsy investigation of the patient with seizures types of seizures and classes epilepsy pseudoseizures origin of seizures treatment of principles. Part 2 Epilepsy throughout the life cycle: seizures in infancy and early childhood children and adolescents with epilepsy adults with epilepsy reproduction and birth defects the inheritence of epilepsy psychologic disturbances and suicide therapeutics. Part 3 Therapeutics: antiepileptic drugs non-pharmaceutical approaches.
Abstract 1922: APOA5 Missense Mutations Associated with Chylomicronemia Sensitive to Fibrate Therapy
Authors: Alvaro Martinez, Gilles Morineau, Fabienne Dufernez, Antoine Crie, Jamila Fruchart-Najib, Pascale Benlian
Journal: Circulation (2008)

Apolipoprotein A5 (APOA5) was recently identified as a major regulator of plasma triglycerides (TG) with specific roles still debated in human. We describe a patient, APOA5 compound heterozygote fo...
Die Ernährung: Physiologie, Pathologie, Therapie.
Authors: Konrad Lang, Rudolf Schoen, R. F. A. Dean
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lehrbuch der Mund- und Rachenkrankheiten.
Authors: Josef Berberich
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical Pathology of Lung Neoplasms
Journal: Thorax (1991)

dilator FEV,.The relation of a particular index to prebronchodilator FEV1 may well vary with differing populations studied, depending on spread of FEV1 values, underlying diagnosis, age and sex distribution, and other factors.Using a measure which is independent of prebronchodilator FEV1, however, will facilitate comparisons between the results of different studies.
Ocular Sequelae of Third Cranial Nerve Palsy
Authors: A C JOHNSTON, J A PRATT-JOHNSON
Journal: JAMA (1963)

The ocular sequelae in nineteen patients who had suffered from a complete paralysis of the third cranial nerve were analyzed. In eleven of these patients, the paralysis was associated with an aneurysm of the internal carotid artery system. None of the cases in this group showed complete recovery of the third nerve function; however, six recovered sufficiently to permit binocular single vision in most fields of gaze. Two cases of aberrant regeneration of the third nerve were diagnosed.Trauma accounted for four cases of third nerve paralysis. One of these recovered completely and one showed features of aberrant regeneration. Of the cases of oculomotor paralysis associated with herpes zoster ophthalmicus, encephalitis, or an obscure etiology (two cases), all recovered completely.
Abstract 9968: Radiofrequency Catheter Ablation for Persistent Atrial Fibrillation Improves Sleep-Disordered Breathing
Authors: Yoshihisa Naruse, Hiroshi Tada, Makoto Satoh, Mariko Yanagihara, Hidekazu Tsuneoka, Yumi Hirata, Takeshi Machino, Hiro Yamasaki, Miyako Igarashi, Kenji Kuroki, Yoko Ito, Yukio Sekiguchi, Kazutaka Aonuma
Journal: Circulation (2011)

Background: Recent studies have suggested an emerging link between sleep apnea and atrial fibrillation (AF). Radiofrequency catheter ablation is becoming an effective therapeutic option for drug-refractory AF. However, the effect of radiofrequency catheter ablation on sleep-disordered breathing has not been sufficiently clarified. Methods: This study included 19 patients (18 men and 1 woman; 62±6 years) with sleep apnea syndrome who underwent radiofrequency catheter ablation for drug refractory, persistent AF. The standard overnight polysomnographic evaluation was performed before and 1 week after the ablation in all patients. The total duration and number of episodes of central or obstructive sleep apnea or hypopnea were analyzed and compared. Results: Among 19 patients, all patients predominantly had obstructive apnea (obstructive apnea index, median 13.8, IQR (interquartile range) 7.1-20.9; central apnea index, 0.2, IQR 0.0-0.5; p&lt;0.001). One week after the ablation, the number of apnea hypopnea index (21, [IQR 12-39] to 10, [IQR 6-24]; p=0.001) and obstructive type of apnea (14, [IQR 7-21] to 7, [IQR 2-16]; p=0.002) were significantly reduced. Median % change of apnea hypopnea index was 42% (IQR 22-60). In 9 (47%) patients, the severity of sleep-disorder breathing improved after the ablation. Furthermore, the sleep-disorder breathing was normalized after the ablation in 2 (11%) patients. In 3 patients who did not maintain sinus rhythm after the ablation, the apnea hypopnea index did not improve, and there was a significant correlation between rhythm control after radiofrequency catheter ablation and % change of apnea hypopnea index (rs=0.63, p=0.004). Body weight (70.8±11.3 to 69.6±10.9 [kg], p&lt;0.001), plasma N-terminal pro B-type natriuretic peptide level (384, [IQR 237-610] to 106 [66-166] [pg/ml], p=0.001), left atrial volume (65±22 to 56±17 [ml], p=0.048), and estimate pulmonary capillary wedge pressure (13±4 to 11±3 [mmHg], p=0.006) were also reduced significantly after the ablation. Conclusions: In patients with sleep apnea syndrome and persistent AF, to restore sinus rhythm by radiofrequency catheter ablation significantly improves obstructive sleep apnea.